Eli Lilly's Foundayo Drug Boosts Stock Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Source: Fool
- Strong Stock Performance: Eli Lilly's stock has surged over 18% since April 30, significantly outperforming the S&P 500's 5% increase, indicating strong market confidence in the company's financial results.
- New Drug Launch: The FDA approval of Foundayo as the first oral weight loss pill is expected to attract more patients, particularly due to its convenience compared to the injectable Zepbound, enhancing its market appeal.
- Sales Growth Potential: Although Foundayo is just starting its commercial journey, CEO David Ricks expressed optimism about its uptake, suggesting that prescriptions and sales may exceed internal expectations, akin to Zepbound's impressive 80% year-over-year sales growth to nearly $4.2 billion in Q1 2023.
- Market Expansion Strategy: Eli Lilly is not only focusing on weight loss drugs but also announced the acquisition of three private vaccine developers at the end of May, demonstrating its commitment to expanding across multiple therapeutic areas and solidifying its leadership in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1105.000
Low
950.00
Averages
1192
High
1500
Current: 1105.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Foundayo Drug Boosts Stock Price
- Strong Stock Performance: Eli Lilly's stock has surged over 18% since April 30, significantly outperforming the S&P 500's 5% increase, indicating strong market confidence in the company's financial results.
- New Drug Launch: The FDA approval of Foundayo as the first oral weight loss pill is expected to attract more patients, particularly due to its convenience compared to the injectable Zepbound, enhancing its market appeal.
- Sales Growth Potential: Although Foundayo is just starting its commercial journey, CEO David Ricks expressed optimism about its uptake, suggesting that prescriptions and sales may exceed internal expectations, akin to Zepbound's impressive 80% year-over-year sales growth to nearly $4.2 billion in Q1 2023.
- Market Expansion Strategy: Eli Lilly is not only focusing on weight loss drugs but also announced the acquisition of three private vaccine developers at the end of May, demonstrating its commitment to expanding across multiple therapeutic areas and solidifying its leadership in the pharmaceutical industry.
See More
Eli Lilly's Retevmo Phase 3 Results Set New Oncology Standard
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 study demonstrates an 83% reduction in the risk of disease recurrence or death for Retevmo in early-stage RET fusion-positive non-small cell lung cancer patients, potentially establishing a new standard of care in the adjuvant setting, significantly enhancing the company's leadership in oncology.
- Survival Rate Improvement: The study also reports a 92% event-free survival rate at 24 months compared to 61% for placebo, a notable difference that not only boosts patient confidence in treatment but may also accelerate the adoption of genomic testing, further solidifying Lilly's market position in precision medicine.
- Strengthening Industry Trends: Lilly's success underscores the importance of precision medicine and biomarker-driven therapies in cancer treatment, likely attracting increased investor interest in other oncology companies with promising Phase 2 and Phase 3 catalysts, thereby driving innovation and growth across the industry.
- Future Outlook: With Lilly's breakthroughs in oncology, the market is keenly anticipating upcoming clinical data from other companies, including NeOnc Technologies and Olema Pharmaceuticals, which could further reshape investor perceptions of the oncology market.
See More
Eli Lilly Poised for Nvidia-Style Growth Surge
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, showcasing its strong competitive position in the rapidly growing weight loss drug market, which is projected to approach $100 billion by the end of the decade.
- Innovation-Driven Growth: The recent launch of Lilly's weight loss drug Zepbound and strong results from late-stage clinical trials indicate that the company's ongoing investment in innovation will bolster its market leadership, further solidifying its advantage in the weight loss sector.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing the $1,000 mark, reflecting investor confidence in its weight loss portfolio, especially following the approval of its oral weight loss drug Foundayo, which has significantly enhanced market expectations for future growth.
- Diversified Product Portfolio: Lilly is actively developing a broad portfolio of weight loss drugs, including both oral and injectable options, and with the positive phase 3 trial data for retatrutide, the company is poised to expand its product line further in the coming years, maintaining its leading position in a competitive market.
See More
Eli Lilly Gains Approval for New Drug, Strengthening Weight Loss Market Leadership
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, demonstrating its strong competitive position in the rapidly growing weight loss drug sector.
- New Product Launch: Lilly received approval for its oral weight loss drug Foundayo in April, with early trends showing promising results, further enriching its weight loss portfolio and positioning the company advantageously in a market approaching $100 billion.
- Successful Clinical Trials: Recently, Lilly reported positive phase 3 trial data for its candidate retatrutide, which, if successful, will complement its existing oral and injectable drugs to create a comprehensive weight loss portfolio catering to patients with varying obesity levels.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing $1,000, as investors express confidence in its high growth potential in the weight loss market, potentially indicating a growth trajectory similar to Nvidia's.
See More
Hanmi Pharm Enters Licensing Agreement with Eli Lilly
- Licensing Agreement Signed: Hanmi Pharm has entered into a licensing agreement with Eli Lilly for the development, manufacturing, and commercialization of its biologic drug candidate Sonefpeglutide, which is expected to significantly enhance Hanmi's market position and revenue potential.
- Stock Price Surge: Following the announcement, Hanmi's shares surged 6.52% to 523,000 Korean Won, reflecting positive market expectations and increased investor confidence in the collaboration.
- Milestone Payment Potential: Under the agreement, Hanmi will receive an upfront payment of $75 million and may earn up to $1.185 billion in additional milestone payments related to clinical development, regulatory approval, and commercialization, greatly enhancing the company's financial flexibility.
- Global Development Rights: Eli Lilly will obtain exclusive rights to develop, manufacture, and commercialize Sonefpeglutide worldwide, while Hanmi focuses on the Korean market, a strategic division that will help both parties maximize their respective gains.
See More
Trump Tightens Iran Deal Terms, Oil Prices Rise
- Oil Price Increase: Crude oil prices rose on Sunday as President Trump reportedly tightened the terms of the Iran deal, reflecting market sensitivity to geopolitical risks that could lead to future supply constraints, thereby impacting global oil price trends.
- Market Reaction: The rise in oil prices may positively affect energy stocks, particularly those reliant on stable oil prices, prompting investors to reassess these companies' profitability and market performance.
- Tech Stock Performance: Nvidia and Tesla, among five tech giants nearing buy points, indicate sustained market interest in high-tech stocks, potentially attracting more investors to focus on these companies' growth potential.
- Investor Sentiment: With the dual impact of rising oil prices and tech stock performance, investor sentiment may become more optimistic, driving overall market upward, especially in energy and technology investment activities.
See More
Eli Lilly's Foundayo Drug Boosts Stock Price
- Strong Stock Performance: Eli Lilly's stock has surged over 18% since April 30, significantly outperforming the S&P 500's 5% increase, indicating strong market confidence in the company's financial results.
- New Drug Launch: The FDA approval of Foundayo as the first oral weight loss pill is expected to attract more patients, particularly due to its convenience compared to the injectable Zepbound, enhancing its market appeal.
- Sales Growth Potential: Although Foundayo is just starting its commercial journey, CEO David Ricks expressed optimism about its uptake, suggesting that prescriptions and sales may exceed internal expectations, akin to Zepbound's impressive 80% year-over-year sales growth to nearly $4.2 billion in Q1 2023.
- Market Expansion Strategy: Eli Lilly is not only focusing on weight loss drugs but also announced the acquisition of three private vaccine developers at the end of May, demonstrating its commitment to expanding across multiple therapeutic areas and solidifying its leadership in the pharmaceutical industry.
See More
Eli Lilly's Retevmo Phase 3 Results Set New Oncology Standard
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 study demonstrates an 83% reduction in the risk of disease recurrence or death for Retevmo in early-stage RET fusion-positive non-small cell lung cancer patients, potentially establishing a new standard of care in the adjuvant setting, significantly enhancing the company's leadership in oncology.
- Survival Rate Improvement: The study also reports a 92% event-free survival rate at 24 months compared to 61% for placebo, a notable difference that not only boosts patient confidence in treatment but may also accelerate the adoption of genomic testing, further solidifying Lilly's market position in precision medicine.
- Strengthening Industry Trends: Lilly's success underscores the importance of precision medicine and biomarker-driven therapies in cancer treatment, likely attracting increased investor interest in other oncology companies with promising Phase 2 and Phase 3 catalysts, thereby driving innovation and growth across the industry.
- Future Outlook: With Lilly's breakthroughs in oncology, the market is keenly anticipating upcoming clinical data from other companies, including NeOnc Technologies and Olema Pharmaceuticals, which could further reshape investor perceptions of the oncology market.
See More
Eli Lilly Poised for Nvidia-Style Growth Surge
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, showcasing its strong competitive position in the rapidly growing weight loss drug market, which is projected to approach $100 billion by the end of the decade.
- Innovation-Driven Growth: The recent launch of Lilly's weight loss drug Zepbound and strong results from late-stage clinical trials indicate that the company's ongoing investment in innovation will bolster its market leadership, further solidifying its advantage in the weight loss sector.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing the $1,000 mark, reflecting investor confidence in its weight loss portfolio, especially following the approval of its oral weight loss drug Foundayo, which has significantly enhanced market expectations for future growth.
- Diversified Product Portfolio: Lilly is actively developing a broad portfolio of weight loss drugs, including both oral and injectable options, and with the positive phase 3 trial data for retatrutide, the company is poised to expand its product line further in the coming years, maintaining its leading position in a competitive market.
See More
Eli Lilly Gains Approval for New Drug, Strengthening Weight Loss Market Leadership
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, demonstrating its strong competitive position in the rapidly growing weight loss drug sector.
- New Product Launch: Lilly received approval for its oral weight loss drug Foundayo in April, with early trends showing promising results, further enriching its weight loss portfolio and positioning the company advantageously in a market approaching $100 billion.
- Successful Clinical Trials: Recently, Lilly reported positive phase 3 trial data for its candidate retatrutide, which, if successful, will complement its existing oral and injectable drugs to create a comprehensive weight loss portfolio catering to patients with varying obesity levels.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing $1,000, as investors express confidence in its high growth potential in the weight loss market, potentially indicating a growth trajectory similar to Nvidia's.
See More
Hanmi Pharm Enters Licensing Agreement with Eli Lilly
- Licensing Agreement Signed: Hanmi Pharm has entered into a licensing agreement with Eli Lilly for the development, manufacturing, and commercialization of its biologic drug candidate Sonefpeglutide, which is expected to significantly enhance Hanmi's market position and revenue potential.
- Stock Price Surge: Following the announcement, Hanmi's shares surged 6.52% to 523,000 Korean Won, reflecting positive market expectations and increased investor confidence in the collaboration.
- Milestone Payment Potential: Under the agreement, Hanmi will receive an upfront payment of $75 million and may earn up to $1.185 billion in additional milestone payments related to clinical development, regulatory approval, and commercialization, greatly enhancing the company's financial flexibility.
- Global Development Rights: Eli Lilly will obtain exclusive rights to develop, manufacture, and commercialize Sonefpeglutide worldwide, while Hanmi focuses on the Korean market, a strategic division that will help both parties maximize their respective gains.
See More
Trump Tightens Iran Deal Terms, Oil Prices Rise
- Oil Price Increase: Crude oil prices rose on Sunday as President Trump reportedly tightened the terms of the Iran deal, reflecting market sensitivity to geopolitical risks that could lead to future supply constraints, thereby impacting global oil price trends.
- Market Reaction: The rise in oil prices may positively affect energy stocks, particularly those reliant on stable oil prices, prompting investors to reassess these companies' profitability and market performance.
- Tech Stock Performance: Nvidia and Tesla, among five tech giants nearing buy points, indicate sustained market interest in high-tech stocks, potentially attracting more investors to focus on these companies' growth potential.
- Investor Sentiment: With the dual impact of rising oil prices and tech stock performance, investor sentiment may become more optimistic, driving overall market upward, especially in energy and technology investment activities.
See More
